Challenges in Discovering Drugs That Target the Protein-Protein Interactions of Disordered Proteins

Area of Science:

• Biochemistry
• Pharmacology
• Neuroscience

Background:

• Protein-protein interactions (PPIs) are fundamental to cellular processes and implicated in diseases such as neurodegeneration.
• Current drug discovery primarily targets individual proteins, not the complex PPIs.
• Developing drugs that modulate PPIs is a significant therapeutic opportunity but faces considerable challenges.

Purpose of the Study:

• To review the difficulties and limitations in discovering drugs that target protein-protein interactions.
• To examine strategies for both direct and indirect modulation of PPIs.
• To use disordered proteins in neurodegenerative diseases as examples to illustrate these challenges.

Main Methods:

• Literature review of existing strategies for targeting protein-protein interactions.
• Analysis of challenges in small molecule drug discovery for PPIs.
• Case study approach focusing on neurodegenerative disease-related proteins.

Main Results:

• Directly targeting PPIs with small molecules is inherently difficult due to the nature of protein interfaces.
• Indirect modulation strategies offer alternative but also present unique hurdles.
• Disordered proteins in neurodegeneration exemplify the complexities in PPI drug discovery.

Conclusions:

• Targeting protein-protein interactions represents a promising but challenging frontier in drug discovery.
• Overcoming current limitations requires innovative strategies for identifying and developing PPI-modulating drugs.
• Further research into PPIs, particularly in the context of neurodegenerative diseases, is essential for therapeutic advancement.